WILLIAMS AND JENSEN, PLLC for ASTRAZENECA PHARMACEUTICALS LP (FORMERLY ASTRAZENECA PHARMACEUTICALS GROUP)
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
21st Century Cures Initiative (House Energy and Commerce Committee) and Innovations for Healthier Americans (Senate Health, Education, Labor and Pensions Committee); possible drug provisions in FY 2017 appropriations bills; Drug safety and drug counterfeiting; Drug importation; 340B Program; Authorized generics; Drug company patent settlements; Senate Finance Committee Chronic Disease Initiative; Implementation of Precision Medicine Initiative; White House Cancer Moonshot; Legislation affecting the ESRD program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
| CHERYL LYNN JAEGER | — |
| KARINA LYNCH | — |
| MELINDA M MAXFIELD | — |
| ERIN BOOK MULLEN | — |
| GEORGE OLSEN | — |
Taxation/Internal Revenue Code TAX
Tax issues affecting the pharmaceutical industry, tax reform issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| GEORGE OLSEN | — |
Medicare/Medicaid MMM
Medicare prescription drug benefit; Drug rebates for Medicare Part D; Part D benefit structure; Payment policies for Medicare Part B Prescription drugs; Independent Payment Advisory Board (IPAB).
| Lobbyist | Covered position, as disclosed |
|---|---|
| JACK STEVEN HART | — |
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
| CHERYL LYNN JAEGER | — |
| KARINA LYNCH | — |
| ERIN BOOK MULLEN | — |
| GEORGE OLSEN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.